<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03953365</url>
  </required_header>
  <id_info>
    <org_study_id>PI 19/41</org_study_id>
    <nct_id>NCT03953365</nct_id>
  </id_info>
  <brief_title>Prophylactic Mesh in Cytoreductive Surgery</brief_title>
  <official_title>Prevention of Incisional Hernia With Prophylactic Mesh in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. A Multicentre, Prospective, Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Fundación Alcorcón</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Fundación Alcorcón</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effectiveness of mesh reinforcement in high-risk patients to prevent incisional
      hernia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on the hypothesis that oncological cytoreductive surgery plus hyperthermic
      intraperitoneal chemotherapy (HIPEC) is associated with an increased risk of developing
      Incisional Hernia in the postoperative period, with an expected incidence of 50% at 24
      months, we designed a prospective, multicenter and randomized clinical study to demonstrate
      the utility of the meshes in the prevention of Incisional Hernia, hoping to reduce the
      incidence to 15% at 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Incisional Hernia</measure>
    <time_frame>four years</time_frame>
    <description>Prevention of Incisional Hernia</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Incisional Hernia</condition>
  <arm_group>
    <arm_group_label>without mesh</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients undergo to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy without prophylactic mesh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>with mesh</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients undergo to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with prophylactic mesh</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prophylactic Mesh</intervention_name>
    <description>Prophylactic Mesh after closure of the abdominal wall after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy</description>
    <arm_group_label>with mesh</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completeness of cytoreduction after surgery (CC-SCORE) CC-0, CC-1

        Exclusion Criteria:

          -  Completeness of cytoreduction after surgery (CC-SCORE) CC-2, CC-3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>May 15, 2019</last_update_submitted>
  <last_update_submitted_qc>May 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Fundación Alcorcón</investigator_affiliation>
    <investigator_full_name>Federico Ochando</investigator_full_name>
    <investigator_title>MEDICAL DOCTOR</investigator_title>
  </responsible_party>
  <keyword>hyperthermic intraperitoneal chemotherapy</keyword>
  <keyword>cytoreduction surgery</keyword>
  <keyword>prophylactic mesh</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Incisional Hernia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

